ReviewAsian journal of andrology
Clinical validity and utility of genetic risk scores in prostate cancer.
Review in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- VADEr: Vision Transformer-Inspired Framework for Polygenic Risk Reveals Underlying Genetic Heterogeneity in Prostate Cancer.medRxiv : the preprint server for health sciences · 2025Article
- Determining the role of genetic risk scores in symptomatic cancer detection.The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Article
- PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry.BMC cancer · 2022Article
- Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.HGG advances · 2022Article
- Implementation and implications for polygenic risk scores in healthcare.Human genomics · 2021Review
- A review of studies examining the association between genetic biomarkers (short tandem repeats and single-nucleotide polymorphisms) and risk of prostate cancer: the need for valid predictive biomarkers.Prostate international · 2020Review
- Validation of a prostate cancer polygenic risk score.The Prostate · 2020Article
- Candidate gene associations reveal sex-specific Graves' disease risk alleles among Chinese Han populations.Molecular genetics & genomic medicine · 2020Article
- Article
- The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer.PloS one · 2020Article
- Association between polygenic risk for tobacco or alcohol consumption and liability to licit and illicit substance use in young Australian adults.Drug and alcohol dependence · 2019Article
- Association between TMPRSS2:ERG fusion gene and the prostate cancer: systematic review and meta-analysis.Central European journal of urology · 2018Review
- A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.Current opinion in urology · 2017Review
- African-American Prostate Cancer Disparities.Current urology reports · 2017Review
- Translation of genomics and epigenomics in prostate cancer: progress and promising directions.Asian journal of andrologyArticle
- Personalized prostate cancer care: from screening to treatment.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current issues related to prostate cancer (PCa) clinical care (e.g., over-screening, over-diagnosis, and over-treatment of nonaggressive PCa) call for risk assessment tools that can be combined with family history (FH) to stratify disease risk among men in the general population. Since 2007, genome-wide association studies (GWASs) have identified more than 100 SNPs associated with PCa susceptibility. In this review, we discuss (1) the validity of these PCa risk-associated SNPs, individually and collectively; (2) the various methods used for measuring the cumulative effect of multiple SNPs, including genetic risk score (GRS); (3) the adequate number of SNPs needed for risk assessment; (4) reclassification of risk based on evolving numbers of SNPs used to calculate genetic risk, (5) risk assessment for men from various racial groups, and (6) the clinical utility of genetic risk assessment. In conclusion, data available to date support the clinical validity of PCa risk-associated SNPs and GRS in risk assessment among men with or without FH. PCa risk-associated SNPs are not intended for diagnostic use; rather, they should be used the same way as FH. Combining GRS and FH can significantly improve the performance of risk assessment. Improved risk assessment may have important clinical utility in targeted PCa testing. However, clinical trials are urgently needed to evaluate this clinical utility as well as the acceptance of GRS by patients and physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.